研究表明,2018年至2022年,在美国有私人保险的青少年中,只有不到0.1%从2018年至2022年接受了性别支持药物。 Study shows less than 0.1% of U.S. adolescents with private insurance received gender-affirming medications from 2018 to 2022.

最近对JAMA儿科的研究发现,2018年至2022年,只有不到0.1%有私人保险的美国青少年接受过诸如青春期阻塞剂或荷尔蒙等性别确认药物。 A recent study in JAMA Pediatrics found that fewer than 0.1% of U.S. adolescents with private insurance received gender-affirming medications like puberty blockers or hormones from 2018 to 2022. 研究分析了510多万名8至17岁年轻病人的保险索赔,发现12岁以下变性病人没有获得确认性别的激素。 The research analyzed insurance claims for over 5.1 million young patients aged 8 to 17, revealing that no transgender patients under 12 were given gender-affirming hormones. 研究报告强调,尽管正在进行公开辩论,而且主要医疗组织也给予支持,但获得这种护理的机会有限。 The study highlights limited access to this care, despite ongoing public debates and the support from major medical organizations. 美国最高法院将很快对相关法律作出裁决。 The U.S. Supreme Court is set to rule on related laws soon.